Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HPN-07 and HPN-07 + NAC in Healthy Subjects
NCT02259595Phase 1Completed
- Sponsor
- Otologic Pharmaceutics, Inc.
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of OKN-007 in noise-induced hearing loss (NIHL) and sensorineural hearing loss (SNHL) (4 arms), sponsored by Otologic Pharmaceutics, Inc. Primary endpoint: Safety and tolerability of single doses of HPN-07, alone and in co-administration with NAC at 48 hours. Started Oct 2014; status: completed.
02
Drugs
OKN-007
03
Conditions
noise-induced hearing loss (NIHL)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT02259595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259595.